Clinical trial nct04512345 roflumilast?

NCT04512345 looks like a ClinicalTrials.gov entry. I can’t pull live data here, but I can help you find and interpret it. Here’s how to look it up and what to expect with roflumilast:

How to find the trial details
- Go to ClinicalTrials.gov
- Enter the exact NCT number: NCT04512345 in the search box
- Open the study page and check:
- Brief Title / Official Title
- Conditions and Interventions (roflumilast and any other treatments)
- Study Type (interventional, observational) and Phase (e.g., Phase 3)
- Status (Recruiting, Active, Not yet recruiting, Completed)
- Sponsor/Collaborators
- Locations
- Primary and secondary endpoints
- Results tab (if results have been posted)

What roflumilast is (quick refresher)
- A selective PDE-4 inhibitor approved in many regions to reduce COPD exacerbations in patients with severe COPD with chronic bronchitis.
- Typical dosing for approved COPD use is 500 mcg once daily; started at 500 mcg every other day in some patients to improve tolerability.
- Common adverse effects: nausea, weight loss, diarrhea, headache; can cause insomnia, anxiety, depression, or other neuropsychiatric symptoms in some individuals.
- Cautions: liver function should be monitored; drug interactions with strong CYP3A4 inhibitors or inducers can affect roflumilast levels.

If you want, tell me:
- The study’s official title or sponsor (if you see it on the page)
- The study’s status or any posted results
I can then summarize the trial design, primary endpoints, and what the results mean in plain language. Alternatively, paste the trial’s key details here and I’ll interpret them for you.